/
We are a commercial stage biotechnology company dedicated to the advancement regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following: Our subsidiary, Creative Medical Technologies, Inc. ( CMT ), was originally created to monetize U.S.
The business is unprofitable at the operating level (-102380.23% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 45.5% YoY. Margins deteriorated 50163.3pp alongside, both lines moving the wrong way.
ROIC dropped from -53.43% to -70.05%, capital efficiency is deteriorating. Operating margin contracted 50163.3pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$3K
▼ -45.5% YoY
Net Income (TTM)
-$6M
▼ -9.1% YoY
Op. Margin
-198049.63%
▼ -50163.3pp YoY
ROIC
-72.09%
▼ -16.6pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$6M
▼ -10.5% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$6M
5Y CAGR: -48.4%
Continue Research